Revance announces proposed public offering of common stock
Revance Therapeutics announced a proposed underwritten public offering in which it will issue and sell $100 million of shares of its common stock. Revance expects underwriters will be granted a 30-day option to purchase from the Company up to an additional 15% of the shares of its common stock. January 15, 2019